EA201591929A1 - Применение пидотимода для лечения синдрома раздраженного кишечника - Google Patents

Применение пидотимода для лечения синдрома раздраженного кишечника

Info

Publication number
EA201591929A1
EA201591929A1 EA201591929A EA201591929A EA201591929A1 EA 201591929 A1 EA201591929 A1 EA 201591929A1 EA 201591929 A EA201591929 A EA 201591929A EA 201591929 A EA201591929 A EA 201591929A EA 201591929 A1 EA201591929 A1 EA 201591929A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
pidotimode
application
intestinal syndrome
infected intestinal
Prior art date
Application number
EA201591929A
Other languages
English (en)
Inventor
Федерико Майлланд
Франческо Скарчи
Маурицио Казерини
Original Assignee
Полихем С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Полихем С.А. filed Critical Полихем С.А.
Publication of EA201591929A1 publication Critical patent/EA201591929A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение направлено на применение пидотимода или его физиологически приемлемой соли для лечения синдрома раздраженного кишечника. В целях терапии настоящее изобретение, пидотимод или его физиологически приемлемую соль, применяют перорально или ректально.
EA201591929A 2013-04-05 2013-04-05 Применение пидотимода для лечения синдрома раздраженного кишечника EA201591929A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/057205 WO2014161594A1 (en) 2013-04-05 2013-04-05 Use of pidotimod to treat irritable bowel syndrome

Publications (1)

Publication Number Publication Date
EA201591929A1 true EA201591929A1 (ru) 2016-02-29

Family

ID=48236865

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591929A EA201591929A1 (ru) 2013-04-05 2013-04-05 Применение пидотимода для лечения синдрома раздраженного кишечника

Country Status (21)

Country Link
US (1) US9446027B2 (ru)
EP (1) EP2981290A1 (ru)
JP (1) JP6049938B2 (ru)
KR (1) KR20150140649A (ru)
CN (1) CN105073137A (ru)
AR (1) AR095961A1 (ru)
AU (1) AU2013385169A1 (ru)
BR (1) BR112015025291A2 (ru)
CA (1) CA2901284A1 (ru)
EA (1) EA201591929A1 (ru)
EC (1) ECSP15041985A (ru)
HK (1) HK1216151A1 (ru)
IL (1) IL241785A0 (ru)
MA (1) MA38456B1 (ru)
MX (1) MX2015014060A (ru)
NI (1) NI201500146A (ru)
PH (1) PH12015502304A1 (ru)
SG (1) SG11201506480VA (ru)
TN (1) TN2015000431A1 (ru)
UA (1) UA113468C2 (ru)
WO (1) WO2014161594A1 (ru)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6946465B2 (en) 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
CN101011362A (zh) * 2007-02-01 2007-08-08 山东益康药业有限公司 匹多莫德分散片及其制备方法和应用
ITTO20070480A1 (it) 2007-07-02 2009-01-03 Marvecspharma Service S R L Impiego di pidotimod, somministrato per via intranasale per potenziare la risposta immunitaria umorale e cellulare antigene-specifica
US20090142769A1 (en) 2007-11-29 2009-06-04 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for determining anti-TNF therapeutic response
CN101623499A (zh) * 2008-07-07 2010-01-13 杨喜鸿 抗生素和匹多莫德的药物组合物及其制备方法和药物应用

Also Published As

Publication number Publication date
BR112015025291A2 (pt) 2017-07-18
MX2015014060A (es) 2016-04-07
TN2015000431A1 (en) 2017-01-03
AR095961A1 (es) 2015-11-25
PH12015502304A1 (en) 2016-02-15
CN105073137A (zh) 2015-11-18
AU2013385169A1 (en) 2015-09-03
CA2901284A1 (en) 2014-10-09
NI201500146A (es) 2016-01-06
ECSP15041985A (es) 2015-11-30
US9446027B2 (en) 2016-09-20
IL241785A0 (en) 2015-11-30
US20160058740A1 (en) 2016-03-03
JP2016515590A (ja) 2016-05-30
MA38456A1 (fr) 2017-11-30
JP6049938B2 (ja) 2016-12-21
WO2014161594A1 (en) 2014-10-09
HK1216151A1 (zh) 2016-10-21
SG11201506480VA (en) 2015-10-29
MA38456B1 (fr) 2018-04-30
KR20150140649A (ko) 2015-12-16
UA113468C2 (uk) 2017-01-25
EP2981290A1 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
EA201692436A1 (ru) Медицинское применение
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
EA201991484A1 (ru) Лекарственные формы энзалутамида
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
EA202090547A3 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
TR201905233T4 (tr) Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.
EA201491854A1 (ru) Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
EA201790912A1 (ru) Гетероциклическое соединение
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EA201700254A1 (ru) Комбинация
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
EA201591185A1 (ru) Применение пидотимода для лечения псориаза
CY1118633T1 (el) Χρηση pidotimod για την θεραπευτικη αγωγη ατοπικης δερματιτιδας
EA201591929A1 (ru) Применение пидотимода для лечения синдрома раздраженного кишечника
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201992386A1 (ru) Замещенные n-арилэтил-2-арилхинолин-4-карбоксамиды и их применение